HOOKIPA Pharma Announces Board of Directors Changes
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing immunotherapeutics based on its arenavirus platform, has announced significant changes to its Board of Directors. Julie O'Neill has been appointed as Non-Executive Chair, succeeding Jan van de Winkel, who is stepping down due to increasing commitments as CEO of Genmab A/S. Additionally, Tim Reilly is also leaving the Board to focus on other professional responsibilities. Both departures are effective August 30, 2024. The Board will now comprise five members, with the vacated seats remaining unfilled. O'Neill expressed gratitude for van de Winkel's seven years of service and Reilly's contributions, emphasizing her commitment to working with the management team for the benefit of shareholders and stakeholders.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), un'azienda che sviluppa immunoterapeutiche basate sulla sua piattaforma di arenavirus, ha annunciato cambiamenti significativi nel suo Consiglio di Amministrazione. Julie O'Neill è stata nominata Presidente Non Esecutivo, succedendo a Jan van de Winkel, che si dimette a causa di crescenti impegni come CEO di Genmab A/S. Inoltre, Tim Reilly lascia anch'esso il Consiglio per concentrarsi su altre responsabilità professionali. Entrambi i cambiamenti avranno effetto dal 30 agosto 2024. Il Consiglio sarà composto ora da cinque membri, con i posti vacanti che rimarranno non occupati. O'Neill ha espresso gratitudine per i sette anni di servizio di van de Winkel e per i contributi di Reilly, sottolineando il suo impegno a collaborare con il team di gestione a beneficio degli azionisti e delle parti interessate.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), una empresa que desarrolla inmunoterapéuticos basados en su plataforma de arenavirus, ha anunciado cambios significativos en su Junta Directiva. Julie O'Neill ha sido nombrada Presidenta No Ejecutiva, sucediendo a Jan van de Winkel, quien renuncia debido a crecientes compromisos como CEO de Genmab A/S. Adicionalmente, Tim Reilly también dejará la Junta para centrarse en otras responsabilidades profesionales. Ambas salidas serán efectivas el 30 de agosto de 2024. La Junta estará compuesta ahora por cinco miembros, con los puestos vacantes que permanecerán sin ocupar. O'Neill expresó su gratitud por los siete años de servicio de van de Winkel y por las contribuciones de Reilly, enfatizando su compromiso de trabajar con el equipo de gestión en beneficio de los accionistas y las partes interesadas.
HOOKIPA Pharma Inc. (NASDAQ: HOOK)는 자신의 아레나바이러스 플랫폼을 기반으로 면역 치료제를 개발하는 회사로, 이사회에 중대한 변화를 발표했습니다. Julie O'Neill이 비상임 의장으로 임명되었으며, Jan van de Winkel은 Genmab A/S의 CEO로서 증가하는 업무로 사임합니다. 또한, Tim Reilly도 다른 직업적 책임에 집중하기 위해 이사회를 떠납니다. 두 사람의 퇴임은 2024년 8월 30일부터 시행됩니다. 이사회는 이제 다섯 명의 구성원으로 이루어지며 공석으로 남아 있는 자리들은 채워지지 않을 것입니다. O'Neill은 van de Winkel의 7년 동안의 봉사와 Reilly의 기여에 감사의 말을 전하며, 주주와 이해관계자들을 위해 경영진과 협력할 것에 대한 자신의 헌신을 강조했습니다.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), une entreprise développant des immunothérapeutiques basées sur sa plateforme d'arénavirus, a annoncé des changements significatifs au sein de son Conseil d'Administration. Julie O'Neill a été nommée Présidente Non-Exécutive, succédant à Jan van de Winkel, qui démissionne en raison de ses engagements croissants en tant que PDG de Genmab A/S. De plus, Tim Reilly quitte également le Conseil pour se concentrer sur d'autres responsabilités professionnelles. Les deux départs prendront effet le 30 août 2024. Le Conseil comptera désormais cinq membres, avec les sièges vacants restant non pourvus. O'Neill a exprimé sa gratitude pour les sept années de service de van de Winkel et pour les contributions de Reilly, soulignant son engagement à travailler avec l'équipe de direction au bénéfice des actionnaires et des parties prenantes.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), ein Unternehmen, das Immuntherapeutika basierend auf seiner Arenavirus-Plattform entwickelt, hat bedeutende Änderungen in seinem Vorstand angekündigt. Julie O'Neill wurde zur nicht-exekutiven Vorsitzenden ernannt und folgt Jan van de Winkel nach, der aufgrund zunehmender Verpflichtungen als CEO von Genmab A/S zurücktritt. Außerdem verlässt Tim Reilly ebenfalls den Vorstand, um sich auf andere berufliche Verpflichtungen zu konzentrieren. Beide Abgänge sind ab dem 30. August 2024 wirksam. Der Vorstand wird nun aus fünf Mitgliedern bestehen, wobei die freigewordenen Sitze unbesetzt bleiben. O'Neill drückte ihre Dankbarkeit für van de Winkels siebenjährige Amtszeit und Reillys Beiträge aus und betonte ihr Engagement, mit dem Managementteam zum Wohle der Aktionäre und Interessengruppen zusammenzuarbeiten.
- Appointment of Julie O'Neill as Non-Executive Chair, potentially bringing fresh perspectives to the Board
- Streamlined Board structure with reduction from seven to five members, potentially improving decision-making efficiency
- Loss of experienced Board members Jan van de Winkel and Tim Reilly
- Potential gap in expertise and industry connections due to departing Board members
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O’Neill as Non-Executive Chair of the Company’s Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities.
“On behalf of the entire Board, I want to thank Jan for his more than seven years of loyal service and inspirational leadership of the Board of Directors and Tim for his insights and perspectives,” said Ms. O’Neill. “We understand their demanding schedules and are grateful for the years of service they provided HOOKIPA. I look forward to working with the management team on behalf of our shareholders and other stakeholders.”
Messrs. van de Winkel’s and Reilly’s board seats will remain unfilled, and the Board will comprise five members.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead. Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
Investors
Chuck Padala
Managing Director, LifeSci Advisors
chuck@lifesciadvisors.com
Media
Tom Davies / Ashe Reardon
tom.davies@kekstcnc.com / ashe.reardon@kekstcnc.com
FAQ
Who is the new Non-Executive Chair of HOOKIPA Pharma's (HOOK) Board of Directors?
Why are Jan van de Winkel and Tim Reilly leaving HOOKIPA Pharma's (HOOK) Board?
How many members will HOOKIPA Pharma's (HOOK) Board of Directors have after the changes?
When do the Board changes at HOOKIPA Pharma (HOOK) take effect?
